
    
      This is a Phase 1, open label, multi center, multiple dose, dose escalation and expansion,
      safety, tolerability, PK, and pharmacodynamics study of PF 06952229 in previously treated
      patients with advanced or metastatic cancers that may have high TGFbeta signatures and EMT
      expression.

      The study includes Parts 1A and 1B, which are dose-escalation for monotherapy and combination
      therapy with enzalutamide, respectively, and Parts 2A and 2B, which are dose expansion for
      monotherapy and combination therapy with enzalutamide, respectively.
    
  